423773-40-4

Basic information

• Product Name: 2-[(2-thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl]-3,4-dihydronaphthalen-1(2H)-one
• Synonyms: 1(2H)-naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro-; 2-[(2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl]-3,4-dihydronaphthalen-1(2H)-one
• CAS NO: 423773-40-4
• Molecular Formula: C₁₄H₁₄N₂OS
• Molecular Weight: 258.3388
• Mol File: 423773-40-4.mol

Chemical Properties

• Boiling Point: 424.32°C at 760 mmHg
• Flash Point: 210.421°C
• Density: 1.326g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.683
• CAS DataBase Reference: 2-[(2-thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl]-3,4-dihydronaphthalen-1(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[(2-thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl]-3,4-dihydronaphthalen-1(2H)-one(423773-40-4)
• EPA Substance Registry System: 2-[(2-thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl]-3,4-dihydronaphthalen-1(2H)-one(423773-40-4)

Safety Data

• Hazardous Substances Data: 423773-40-4(Hazardous Substances Data)

Upstream product

• 157058-44-1 2-(imidazol-4-ylmethyl)-1-tetralone 

Relevant articles and documents

NOVEL METHODS AND COMPOSITIONS FOR ALLEVIATING PAIN

The present invention provides a method for the long-term relief of chronic pain in a subject by activating in the subject an analgesic α-adrenergic receptor in the absence of α-2A receptor activation over a period of at least three days, such that relief of chronic pain is maintained in the absence of continued activation of said receptor. The analgesic α-adrenergic receptor can be, for example, the α-2B receptor.

4-SUBSTITUTED IMIDAZOLE-2-THIONES AND IMIDAZOL- 2-ONES AS AGONISTS OF THE ALPHA- 2B AND ALPHA-2C ADRENERGIC RECEPTORS

Compounds of Formula (I): where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardivascular and/or sedatory activity. These compounds of Formula (I) are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula (I) where X is O also have the advantageous property that they have no or only minimal cardivascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardivascular and/or sedatory activity.